Cargando…
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular mortality in individuals with type 2 diabetes, although the mechanism(s) of this benefit remain poorly understood. Because changes in cardiac bioenergetics play a critical role in the pathophysiology of heart failur...
Autores principales: | Verma, Subodh, Rawat, Sonia, Ho, Kim L., Wagg, Cory S., Zhang, Liyan, Teoh, Hwee, Dyck, John E., Uddin, Golam M., Oudit, Gavin Y., Mayoux, Eric, Lehrke, Michael, Marx, Nikolaus, Lopaschuk, Gary D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234616/ https://www.ncbi.nlm.nih.gov/pubmed/30456329 http://dx.doi.org/10.1016/j.jacbts.2018.07.006 |
Ejemplares similares
-
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017) -
The use of chromoendoscopy for surveillance of inflammatory bowel disease
por: Lichtenstein, Gary R., et al.
Publicado: (2018) -
Trade in wild animals: a disaster ignored
por: The Lancet Infectious Diseases
Publicado: (2003) -
A European CDC
por: The Lancet Infectious Diseases
Publicado: (2003) -
An appropriate response to SARS
por: The Lancet Infectious Diseases
Publicado: (2003)